EchoVest
EM-TECH Global Holdings Corporation

The Next Generation of
Cardiac Intelligence

AI-guided cardiac imaging designed to expand access, improve consistency, and support scalable cardiovascular care.

$9B
U.S. Imaging Market
$9B
Market Opportunity
78%
Gross Margin
510(k)
Filed
FDA Regulatory Filing
58k+
Cardiovascular Studies
Executive Summary

EchoVest is a wearable, AI-powered cardiac imaging platform that significantly reduces healthcare's dependency on specialized sonographers. Combining advanced robotic hardware, adaptive acoustics, and a proprietary AI diagnostic engine, EchoVest delivers ICAEL-quality echocardiography with minimal operator dependency. The company has filed FDA 510(k) K254143 and a USPTO patent application. Raising $6M seed round; full terms available in offering materials to qualified investors.

Investment Highlights

FDA 510(k) K254143
Submitted Dec 22, 2025 · Class II Medical Device
USPTO Patent Application Filed
Full-stack IP protection
Revenue Trajectory
$0.9M (2026) → $120M (2030) · 78% gross margin
30TB Clinical Dataset
Proprietary cardiovascular echo data moat

The Structural Crisis

7,000+
Unfilled sonographer positions nationwide
$400B
Potential savings via early cardiac intervention
70%
Of cardiac events lack adequate pre-screening

Why Now

Healthcare is entering a convergence point

AI Maturity

AI has reached real-time medical inference capability — designed to enable advanced clinical decision support at scale.

Rising Demand

Cardiovascular demand rising globally. Critical sonographer shortages are limiting access to essential diagnostics.

Point-of-Care Shift

Point-of-care diagnostics are becoming the standard of care, decentralizing imaging away from hospital radiology departments.

Market Validation

Butterfly Network and GE Healthcare validated the market — but remain entirely operator-dependent. EchoVest is designed to address that constraint.

"EchoVest is designed to dramatically reduce operator dependency."

Technology Stack

A Symbiotic System of Hardware and AI

01
Precision

Hardware Layer

  • Wearable multi-probe system
  • Precision robotic probe positioning
  • Integrated probe architecture
  • Multi-axis precision per probe
  • High-precision positioning
02
Adaptive

Control Layer

  • Real-time actuation via embedded controllers
  • Sensor-driven positioning and safety logic
  • Adaptive multi-frequency optimization
03
AI AI Engine

AI Layer

  • AI-powered image acquisition guidance
  • Automated interpretation and clinical workflow
  • Future: Advanced image authentication
  • High-accuracy ejection fraction measurement
  • 70% reduction in interpretation time
04
BIOMETRIC

Data Layer

  • 15+ years of clinical cardiovascular data
  • Cardiologist-confirmed imaging
  • Structured for AI training and validation

Competitive Matrix

Feature EchoVest Butterfly iQ Caption Health GE / Philips
Wearable ✓ Yes ✗ No N/A ✗ No
Multi-probe ✓ Yes ✗ No N/A ✓ Yes
AI Guidance ✓ Yes Limited ✓ Yes Limited
Robotic Positioning ✓ Yes ✗ No ✗ No ✗ No
Advanced Data Security ✓ Yes ✗ No ✗ No ✗ No
Autonomous Operation ✓ Yes ✗ No Partial ✗ No

Strategic Moats

Integrated Hardware-Software Patent

Full-stack IP protection across hardware and AI software layers

Regulatory Lock-in

ICAEL protocol automation creates a powerful regulatory moat

First-Mover Advantage

5+ year head start — no direct competitor offering comparable operator-independent workflow

The Data Advantage

EchoVest is not just a device. It is a data-driven platform.

20–30 TB
Curated Cardiovascular Imaging Data
15+ Years
Clinical data collection
100%
Board-certified cardiologist verification
AI-Ready
Structured for training & validation

Data Accumulation Over Time

2010
~2 TB
2015
~5 TB
2018
~9 TB
2022
~18 TB
2025
30 TB+

"This dataset enables faster model training, higher accuracy in real-world conditions, and a defensible competitive advantage. Competitors cannot easily replicate this foundation."

$9 Billion U.S. Cardiac Imaging Market

Click a segment to learn more

Hospitals
$3.6B
40% of total market

Large health systems with high-volume echo labs. Primary beachhead market with established reimbursement pathways (CPT 93306 at ~$380/study).

Outpatient Clinics
$2.25B
25% of total market

Cardiology offices and multi-specialty clinics. High growth potential as EchoVest is designed to enable cardiac imaging without a dedicated sonographer on staff.

Telehealth / Remote
$1.35B
15% of total market

Fastest growing segment. Remote patient monitoring and virtual care integration — EchoVest uniquely enables fully remote cardiac imaging.

Sports Medicine
$1.08B
12% of total market

Pre-participation cardiac screening for athletes. FDA clearance enables non-hospital cardiac assessment in field environments.

International / Gov.
$0.72B
8% of total market

Military, government health agencies, and international markets including Saudi Arabia Vision 2030 deployment potential.

Market Convergence — Three Growth Vectors

EchoVest sits at the intersection of three accelerating markets

6.8%
Ultrasound Market CAGR
MarketsandMarkets
15.9%
POCUS Market CAGR
Fortune Business Insights
28.6%
AI Ultrasound CAGR
Grand View Research
Ultrasound POCUS AI Ultrasound EchoVest

Revenue Architecture

<$2,500
Manufacturing Cost
~$10,000
Selling Price
~80%
Gross Margin

Revenue Streams

Recurring
Device Leasing
$1,000/month

Full-service device lease with maintenance, updates, and support included.

Recurring
SaaS Subscription
$500/month

AI diagnostic platform, cloud storage, reporting, and analytics dashboard.

Variable
Per-Scan Fees
$50/scan

Transaction fee per completed autonomous echo study — aligned incentives.

One-Time
Direct Sales
$7.5K–$15K

Capital purchase for enterprise accounts and large health systems.

5-Year Financial Projections

Revenue vs. EBITDA (2026–2030)

$6M Seed Round Allocation

Deployment Curve (Units)

2025 Sprint Milestones

Jan 2025
The Latent Phase
Idea fully formed — concept development and research foundation established.
Feb 2025
IGNITION
AI validation phase — core diagnostic algorithms validated against clinical benchmarks.
Mar 2025
Deep AI Immersion
Architecture formation — Proprietary AI pipeline architecture finalized.
Apr 2025
System Convergence
"AI without images is blind" — hardware-AI integration architecture locked.
May 2025
Entity Formation
EM-TECH Global Holdings Corporation incorporated. Corporate structure established.
Jun 2025
Engineering & Materials
3D printing and advanced materials sourced and tested for wearable vest construction.
Sep 2, 2025
MILESTONE
The Breakthrough
First prototype printed and assembled — fully functional wearable prototype demonstrated.
Oct 2025
Strategy Maturity
"AI-enabled diagnostic infrastructure" — go-to-market strategy and clinical pilot planning complete.
Dec 2025
MILESTONE
The Lock
USPTO patent application filed. FDA 510(k) K254143 submitted Dec 22, 2025.

Regulatory Pathway

Dec 22, 2025
510(k) Submitted
150-Day Review
FDA Review Period
Mid-2026
Milestone Target
Class II Medical Device 21 CFR 892.1570 Predicate K092164

Leadership Team

EM

Enayatullah Motahedy

Founder & CEO
  • 20+ years clinical echocardiography experience
  • Inventor — hardware + AI diagnostic system
  • FDA 510(k) and USPTO patent filer
  • RDCS certified
AM

Dr. Azita Moalemi, MD, FACC

Co-Founder & CMO
  • Board-certified cardiologist
  • Amelia Heart & Vascular Center
  • ICAEL credentialing expert
  • FACC — Fellow, American College of Cardiology

Strategic Partners

Amelia Heart & Vascular Center
Clinical Pilot Partner
James Pravel, Esq. & Kirkland & Ellis
Legal Counsel
Kingdom of Saudi Arabia Vision 2030
International Partnership

Saudi Arabia — Strategic Expansion Brief

EchoVest as National-Scale Cardiac Infrastructure for Vision 2030

$900M+
Vision 2030 Healthcare Investment Committed
Healthcare Impact

A Cardiovascular Crisis Requiring Advanced Solutions

37%of all KSA deaths from CVD
23.7%diabetes prevalence
70%obesity rate

Saudi Arabia faces one of the world’s highest cardiovascular disease burdens. Vision 2030 targets reducing CVD mortality by 30% and expanding primary care access to 95% of citizens. EchoVest is designed to enable scalable cardiac screening — significantly reducing dependency on specialist labor.

Digital Infrastructure

Aligned with Saudi Digital Health Strategy

KSA’s digital health agenda prioritizes AI-first diagnostics, cloud-native platforms, and interoperable health records. EchoVest is natively designed for this architecture — AI-powered diagnostic engine, cloud reporting, and EMR integration. SFDA registration accelerated by FDA 510(k) predicate, enabling market entry as early as 2027.

Pilot Pathway

Phased National Deployment

2028
Pilot 3–5 hospitals in Riyadh & Jeddah
2029
Hajj cardiac screening at Mina / Arafat (2M+ pilgrims)
2030
National rollout — 50+ facilities across KSA
Saudization Alignment

Enabling National Workforce Independence

Saudi Arabia faces the same global sonographer shortage magnified by Saudization requirements. EchoVest significantly reduces dependency on specialized sonographer staffing, enabling Saudi nationals to operate advanced cardiac imaging with minimal training. This directly supports Vision 2030 workforce localization mandates.

National-Scale Upside

The Hajj Health Opportunity + National Infrastructure

2M+ annual Hajj pilgrims undergo extreme heat and physical exertion, creating elevated cardiac risk at unprecedented scale. EchoVest is designed to enable large-scale cardiac screening during Hajj at Mina/Arafat — a deployment scenario no existing device can match. Beyond Hajj, a national cardiac imaging network positions EchoVest as foundational health infrastructure across 13 KSA regions.

Saudi MOH Saudi FDA NEOM Health King Faisal Specialist Hospital Saudi Health Council Hajj & Umrah Ministry PIF KAUST

EchoVest in Action

See how AI-guided cardiac imaging works

Probe Array Active
Step 1 of 5

Vest Application

Multi-probe wearable positioned on patient's chest. The EchoVest automatically detects placement and activates the probe array. Minimal operator positioning required.

Initializing probe array...
P1
87%
P2
94%
P3
91%
P4
78%
P5
96%
Step 2 of 5

AI Probe Positioning

AI-guided robotic actuators find optimal acoustic windows autonomously. Robotic actuators micro-adjust each probe in real-time for maximum signal quality.

Optimizing acoustic windows...
ACQUIRING...
Step 3 of 5

Image Acquisition

Autonomous image capture — minimal operator intervention. Adaptive frequency probes capture complete cardiac anatomy across all standard views.

Capturing frames... 0/240
AI DIAGNOSTIC READOUT
Ejection Fraction --
LV Mass Index --
E/A Ratio --
STATUS NORMAL
Proprietary AI Pipeline
Step 4 of 5

AI Analysis

Proprietary AI pipeline delivers instant interpretation. EchoVest achieves cardiologist-level accuracy in ejection fraction measurements — significantly reducing interpretation time.

Analysis complete
EV
EchoVest Report
Generated:
Ejection Fraction 62% — Normal
LV Mass Index 88 g/m² — Normal
E/A Ratio 1.4 — Normal diastolic function
Wall Motion No regional abnormality
Overall Normal Cardiac Function
Step 5 of 5

Report Generated

Complete diagnostic report in under 90 seconds. Fully structured, cardiologist-ready echocardiogram report — minimal human intervention required throughout the workflow.

Report ready for physician review
3s per step
The Ask
$6,000,000
Terms available to qualified investors upon request
506(c)
Reg D Qualified Investor Offering
Board Seat
For Lead Investor (≥$2M)
Pro-Rata
Rights for All Investors

Use of Funds

Regulatory & Clinical 30% $1.8M
R&D & AI 25% $1.5M
Commercial 25% $1.5M
Manufacturing 20% $1.2M

"EchoVest represents a shift from manual imaging to intelligent acquisition. We are building a hardware platform, an AI system, and a data-driven ecosystem. This is not just a device — this is infrastructure for the future of cardiac diagnostics."

Get in Touch
Enayatullah Motahedy, RDCS
emotahedy@echovestx.com
EM-TECH Global Holdings Corporation